Allakos Is A Cautionary Tale Of Biopharmaceutical Investing


As recently shown, investing in Allakos (NASDAQ:ALLK) proves the inherent danger within the biopharmaceutical sector. After reaching a 52-week high of more than $157, ALLK stock plunged late in December and now sits just above $8 per share.

Biopharma companies often live and die by the initial success of a single compound. Once a compound receives the Food and Drug Administration (FDA) go-ahead, the sky is often the limit. An early drug’s success drives a strong revenue stream, setting up future successes.

But what happens when things go wrong? Allakos recently gave us some insight into what that looks like.

See what happened to ALLK stock here

The post Allakos Is a Cautionary Tale of Biopharmaceutical Investing appeared first on InvestorPlace.